Last 33 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -25.54 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 15.39 | 9.13 | 14.96 | 18.59 | 24.46 | 20.50 | 18.60 | 14.09 | 220.94 | 439.19 | 547.92 | 6.54 | 1009.03 | 263.17 | 420.66 | 346.50 | 152.14 | 1087.65 | 4.52 | 218.52 | 47.01 |
| — | -55.5% | -19.6% | +31.9% | -88.9% | -95.3% | -96.6% | +115.3% | -78.1% | +66.9% | +30.3% | -98.1% | +563.2% | -75.8% | +9216.6% | +58.6% | +223.6% | +48.4% | -89.1% | -95.3% | -99.7% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 16.44 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 874.03 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 36.31 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.4% | 94.2% | 93.8% | 94.6% | 90.0% | 94.6% | 96.7% | 97.7% | 64.6% | 78.1% | 72.4% | 99.7% | 65.7% | 85.4% | 63.5% | 64.3% | 65.4% | -118.6% | 99.1% | 20.4% | 88.0% |
| — | -0.4% | -3.0% | -3.2% | +39.4% | +21.1% | +33.5% | -2.0% | -1.8% | -8.5% | +14.0% | +55.0% | +0.5% | +172.0% | -35.9% | +215.0% | -25.6% | -412.5% | -0.7% | -79.6% | -12.0% | |
| Operating Margin | -113.3% | -3.3% | -43.9% | -54.5% | -120.1% | -120.3% | -121.4% | -89.5% | -3842.7% | -7018.7% | -8096.8% | 0.2% | -10167.1% | -3854.6% | -8903.0% | -6909.3% | -6910.8% | -38200.0% | -108.7% | -10252.5% | -1285.2% |
| — | +97.3% | +63.8% | +39.1% | +96.9% | +98.3% | +98.5% | -55169.2% | +62.2% | -82.1% | +9.1% | +100.0% | -47.1% | +89.9% | -8089.0% | +32.6% | -437.7% | -498.9% | +37.5% | +71.7% | +98.8% | |
| Net Margin | -145.3% | -16.1% | -62.5% | -84.3% | -127.9% | -151.4% | -164.5% | -143.5% | -4506.1% | -5931.2% | -3388.2% | -16.7% | -9636.0% | -4326.5% | -9622.1% | -7675.6% | -7357.8% | -40632.8% | -13.4% | -11593.7% | -1142.1% |
| — | +89.4% | +62.0% | +41.2% | +97.2% | +97.4% | +95.1% | -760.6% | +53.2% | -37.1% | +64.8% | +99.8% | -31.0% | +89.4% | -71896.0% | +33.8% | -544.2% | -510.8% | +92.5% | +67.2% | +98.8% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -78.6% | -3.4% | -11.8% | -14.2% | -20.4% | -17.6% | -18.5% | -18.6% | -33.5% | -22.2% | -8.9% | -5.0% | -28.0% | -30.6% | -28.0% | -22.4% | -20.4% | -17.3% | -1.2% | -21.5% | -16.4% |
| — | +80.9% | +36.6% | +23.5% | +39.0% | +20.8% | -107.5% | -268.4% | -19.5% | +27.3% | +68.0% | +77.5% | -37.5% | -77.0% | -2276.6% | -4.4% | -24.1% | -3.1% | +86.7% | -18.5% | -2.0% | |
| ROIC | -524.0% | — | — | -50.2% | — | — | -67.4% | — | — | -83.4% | -83.2% | 0.2% | -463.2% | -201.1% | -133.7% | -102.7% | -95.0% | -58.9% | -22.2% | -33.3% | -26.2% |
| — | — | — | — | — | — | +19.0% | — | — | +58.5% | +37.7% | +100.2% | -387.7% | -241.4% | -502.8% | -208.4% | -263.1% | -175.0% | -71.0% | -2.1% | +20.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 891.58 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.62 | 2.09 | 1.23 | 1.44 | 2.62 | 3.88 | 5.19 | 4.57 | 4.67 | 3.19 | 4.59 | 5.54 | 3.32 | 5.54 | 3.93 | 5.72 | 4.52 | 5.39 | 5.46 | 6.92 | 6.58 |
| — | -46.0% | -76.3% | -68.4% | -43.9% | +21.4% | +13.1% | -17.5% | +40.6% | -42.4% | +16.7% | -3.2% | -26.5% | +2.8% | -28.1% | -17.3% | -31.3% | -19.3% | -20.8% | -30.6% | -2.1% | |
| Quick Ratio | 2.52 | 2.03 | 1.17 | 1.40 | 2.52 | 3.76 | 5.08 | 4.54 | 4.67 | 3.19 | 4.59 | 5.54 | 3.32 | 5.54 | 3.93 | 5.72 | 4.52 | 5.39 | 5.46 | 6.92 | 6.58 |
| — | -46.0% | -77.0% | -69.1% | -45.9% | +17.8% | +10.8% | -17.9% | +40.6% | -42.4% | +16.7% | -3.2% | -26.5% | +2.8% | -28.1% | -17.3% | -31.3% | -19.3% | -20.8% | -30.6% | -2.1% | |
| Interest Coverage | -12.84 | -0.07 | -10.74 | -2.15 | -15.44 | -14.89 | -3.83 | -3.02 | -7.93 | -6.12 | -2.29 | -0.54 | -7.40 | -7.84 | -6.80 | -6.09 | -6.03 | -6.07 | 0.87 | -8.90 | -9.06 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BBIO stock.
BridgeBio Pharma, Inc.'s current P/E is -25.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BridgeBio Pharma, Inc.'s current operating margin is -113.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BridgeBio Pharma, Inc.'s business trajectory between earnings reports.